Dr. Manik Chandra Shill has completed his PhD from Tokushima University, Japan. He worked in the development of anti-allergic lead(s) from Ayurvedic plants through the suppression of PKCδ dependent signaling pathway. Dr. Shill is expert in molecular pharmacology, toxicology and natural product chemistry. Before joining at North South University, Dr. Shill worked in pharmaceutical industry, market research and hospital to different capacities. Dr. Shill is highly experienced in hospital pharmacy with international training. Dr. Manik Chandra Shill is now working as Assistant Professor in the Department of Pharmaceutical Sciences. His research interests are pharmacology, toxicology, natural product chemistry, hospital and clinical pharmacy practices. Dr. Shill has published 65 pear reviewed journals.
RESEARCH, TEACHING, or OTHER INTERESTS
Pharmacy, Pharmacology, Toxicology and Pharmaceutics, Drug Discovery, Immunology and Allergy
Optimized Lipid Nanoparticles for Pioglitazone Delivery: Molecular Docking Insights and In Vivo Efficacy in Nonalcoholic Steatohepatitis Shimul Halder, Tanveer Hossain, Najibah Nasrin, Rumman Reza, Md. Nazmus Samdani, et al. Nano Life, 2026 Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with limited therapeutic options, where pioglitazone (PGZ), a PPAR-[Formula: see text] agonist, has shown promise but suffers from poor solubility and systemic side effects. In this study, we developed and optimized lipid nanoparticles (LNP-PGZ) to enhance the targeted delivery and therapeutic efficacy of PGZ for the treatment of NASH. The formulation was designed to improve solubility and stability, and was characterized through detailed physicochemical analyses, including particle size distribution and in vitro dissolution studies. The optimized LNP-PGZ exhibited a particle size of 56.7 nm, a PDI of 0.113, an EE% of 85% and a DL% of 8.5%. Moreover, the optimized LNP-PGZ exhibited a controlled drug-release profile compared with free PGZ, suggesting improved therapeutic potential. Molecular docking studies further supported the formulation’s effectiveness by demonstrating strong binding affinity of PGZ for key NASH-related targets, including PPAR-[Formula: see text] and STK25, highlighting its potential to modulate metabolic and inflammatory pathways. In vivo efficacy was evaluated in a rat model of NASH induced by a high-fat diet (HFD). Furthermore, LNP-PGZ significantly reduced liver damage in rats with HFD-induced hepatic injury, with 91.7% ([Formula: see text]) reduction in ALT and 86.8% ([Formula: see text]) in AST (Group IV) compared to the disease control (Group II). These findings collectively suggest that LNP-PGZ not only enhances its solubility and bioavailability but also amplifies its therapeutic benefits in NASH, potentially reducing off-target effects. This integrated approach, combining molecular modelling and in vivo validation, offers a promising platform for advancing safer, more effective treatments for liver diseases, such as NASH.
Swertia chirayita Ameliorates Acrylamide-Induced Hepatorenal Toxicities and Oxidative Damage Through Modulating Biomarkers and Proinflammatory Genes Rumky Rahman, Zasia Hossain Tishe, Sudip Saha, Hemayet Hossain, Murad Hossain, et al. Journal of Food Biochemistry, 2026 Background Acrylamide (ACR), used in various food industries, leads to a number of harmful effects, including nephrotoxicity and hepatotoxicity in humans. In this study, we aimed to explore the protective potential of Swertia chirayita against ACR‐induced hepatorenal toxicities and the underlying mechanism in rats. Method Liver and kidney damage was induced using ACR in the male Wistar rats. The ethanolic extract of S. chirayita was used to evaluate the protective effects by analyzing oxidative stress markers, proinflammatory gene expression, and histological changes. Results Experimental results showed that treatment with S. chirayita extract (250 mg/kg and 500 mg/kg) reduced the serum level of liver function markers AST, ALT, ALP, and kidney function markers creatinine and BUN in the ACR rats. Further analysis showed that S. chirayita notably normalized the aberrant level of oxidative stress markers NO, AOPP, and antioxidant enzymes SOD and GSH in the liver and kidney. ACR administration also increased the level of TNF‐α and IL‐1β in the liver and kidney of the ACR rats, which was downregulated by S. chirayita treatment. Histological data revealed that the morphology of the liver and kidney in ACR rats was irregular, and there was a significant accumulation of collagen. Treatment with S. chirayita markedly regularized these changes. Conclusion Our study suggests that the ethanolic extract of S. chirayita has the potential against ACR‐induced hepatorenal damage in rats by balancing oxidative stress and inflammatory response.
Nanoliposomal Formulation of Gynura procumbens Leaf Extract Potentiates Hepatorenal Protection in Cisplatin-Induced Rats Leon Bhowmik, Ashikur Rahaman, Madhobi Karmakar, S. M. M. Sharif Nowaz Antu, Zahidul Islam Zahid, et al. Food Science and Nutrition, 2025 Gynura procumbens, commonly known as longevity spinach, is traditionally used in Southeast Asia for its hepatoprotective, anti‐inflammatory, antihypertensive, and antihyperglycemic properties. This study aimed to enhance the hepatorenal protective effects of G. procumbens leaf extract (GLE) by incorporating it into a nanoliposomal drug delivery system (LIP), thereby improving its dispersibility/solubility and therapeutic efficacy. The resulting nano‐formulation, LIP–GLE, produced micelles with an average size of 112 ± 2.6 nm, showing a 6.6‐fold and 4.6‐fold improvement in dispersibility in water and simulated gastric fluid, respectively, compared to GLE. In a rat model of cisplatin‐induced acute hepatorenal injury (7.5 mg/kg, i.p.), oral administration of LIP–GLE (75 mg GLE/kg) significantly improved liver and kidney function, as indicated by reduced serum levels of ALT, AST, ALP, BUN, and creatinine. Histopathological investigations further confirmed reduced tissue damage in the liver and kidneys. Additionally, LIP–GLE enhanced antioxidant enzyme activities (SOD, GSH) and reduced oxidative stress markers (NO, AOPP), indicating strong protective effects against cisplatin‐induced oxidative injury. These findings demonstrate that liposomal encapsulation significantly enhances the bioavailability and therapeutic potential of GLE, making it a promising approach for enhancing the nutraceutical potential of G. procumbens.
Gynura procumbens leaf extract-loaded self-microemulsifying drug delivery system offers enhanced protective effects in the hepatorenal organs of the experimental rats Manik Chandra Shill, Md. Faisal Bin Jalal, Madhabi Lata Shuma, Patricia Prova Mollick, Md. Abdul Muhit, et al. Plos One, 2025 Gynura procumbens, known as longevity spinach, is a plant traditionally used in tropical Asian countries for its anti-inflammatory, hepatoprotective, anti-hypertensive, and anti-hyperglycemic properties. The current study aimed to enhance the hepatorenal protective activity of Gynura procumbens leaf extract (GLE) by developing a self-microemulsifying drug delivery system (SMEDDS). SMEDDS-GLE exhibited the formation of small micelles with a mean droplet size of 231 nm. This resulted in a significant enhancement in the dispersion of GLE in water, as evidenced by a dispersibility that was at least 4.8 times greater than that of GLE alone. In the rat model of hepatic injury induced by cisplatin (7.5 mg/kg, i.p.), the administration of SMEDDS-GLE (75 mg-GLE/kg, p.o.) significantly reduced liver damage, observed by histological examination and reduced levels of plasma biomarkers associated with hepatic injury. Furthermore, according to histological examination findings and plasma biomarkers assessment, SMEDDS-GLE enhanced the nephroprotective benefits of GLE in the rat model of acute kidney injury. Based on these findings, a strategic application of the SMEDDS-based approach could be a viable choice to enhance GLE’s nutraceutical properties.
Improved Biopharmaceutical Performance of Coenzyme Q10 Through Solid Lipid Nanoparticles for Enhanced Brain Delivery Shimul Halder, Faria Nasrin, Manik Chandra Shill, Madhabi Lata Shuma, Md. Zakir Sultan, et al. Scientifica, 2025 Coenzyme Q10 (CoQ) is a powerful antioxidant with neuroprotective characteristics; nevertheless, its clinical use is constrained by inadequate solubility, diminished bioavailability, and limited blood–brain barrier (BBB) penetration. Solid lipid nanoparticles (SLNs) offer a promising approach to improve the biopharmaceutical characteristics and targeted delivery of CoQ to the brain. This study focuses on the strategic formulation and optimization of SLN‐CoQ to improve solubility, oral absorption, and BBB permeability. The SLNs with drug loading of 2.5% (w/w) were prepared using a solvent injection technique and physicochemically characterized employing encapsulation efficiency, drug loading, particle size, zeta potential, surface morphology, crystallinity, in vitro drug release behavior, and mucus penetrating behavior. Pharmacokinetic studies were conducted in rats (100 mg‐CoQ/kg, p.o.) after oral administration to elucidate the possible enhancement in the oral absorption of CoQ. The SLN‐CoQ (F2) exhibited favorable physicochemical characteristics, including optimal particle size (91.6 ± 8.2 nm), zeta potential (−41.7 ± 1.03 mV), high encapsulation efficiency (85.2 ± 5.0), distinct surface morphology, reduced crystallinity, enhanced drug release, and better mucus penetration than crystalline CoQ. In the dissolution test, SLN‐CoQ demonstrated a significant enhancement in the dissolution profile of CoQ as exhibited by an 83.6‐fold higher dissolved amount of CoQ in 120 min in water in the F2 formulation ratio. Moreover, in the artificial mucus test, a 42‐fold increase in mucus permeation was observed for the F2 formulation compared to the crystalline drug. Orally administered CoQ exhibited a higher systemic exposure of CoQ (3.6‐fold higher) in SLLN‐CoQ compared to crystalline CoQ, with prolonged circulation time and improved tissue distribution (3‐fold higher) in rats. The findings suggest that SLN‐CoQ offers a feasible nanotechnological method for enhanced drug transport to the brain, potentially aiding therapeutic approaches for neurodegenerative diseases, including Parkinson’s and Alzheimer’s.
Gigantol, a promising natural drug for inflammation: a literature review and computational based study Raihan Chowdhury, Shimul Bhuia, Asraful Islam Rakib, Sakib Al Hasan, Manik Chandra Shill, et al. Natural Product Research, 2025 Gigantol, a bibenzyl compound extracted from various medicinal plants, has shown a number of biological activities, making it an attractive candidate for potential medical applications. This systematic review aims to shed light on gigantol’s promising role in inflammation treatment and its underlying mechanisms. Gigantol exhibits potential anti-inflammatory properties in pre-clinical pharmacological test systems. It effectively reduced the levels of pro-inflammatory markers and arachidonic acid metabolites through various pathways, such as NF-κB, AKT, PI3K, and JNK/cPLA2/12-LOX. The in-silico investigations demonstrated that the MMP-13 enzyme served as the most promising target for gigantol with highest binding affinity (docking score = −8.8 kcal/mol). Encouragingly, the absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis of gigantol confirmed its compatibility with the necessary physiochemical, pharmacokinetic, and toxicity properties, bolstering its potential as a drug candidate. Gigantol, with its well-documented anti-inflammatory properties, could be a promising agent for treating inflammation in the near future. Graphical Abstract
Phytol: A review of biomedical activities Muhammad Torequl Islam, Eunüs S. Ali, Shaikh J. Uddin, Subrata Shaw, Md Amirul Islam, et al. Food and Chemical Toxicology, 2018
Medication practices in Bangladesh-roles of pharmacists at current circumstances International Journal of Pharmacy and Pharmaceutical Sciences, 2011
Investigation of antibacterial activities of ethanol extracts of musa paradisiaca lam Journal of Applied Pharmaceutical Science, 2011
Assessment of cytotoxicity, antibacterial activity and phytochemical screening of ethanol extract of phyllanthus acidus l. (family: Euphorbiacceae) bark Journal of Applied Pharmaceutical Science, 2011
Antidiarrheal, analgesic and antioxidant activities of Trapa bispinosa Roxb. fruits Research Journal of Pharmacy and Technology, 2011
